Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 2Solid Tumors 1Recurrence 1Myelodysplastic Syndromes 1Metastatic Solid Tumors 1Leukemia, Myelomonocytic, Chronic 1Advanced Malignant Neoplasm 1

Interventions

pembrolizumab 4Injections 3Nivolumab 2Docetaxel 2taxane 1pazopanib 1palbociclib 1lenvatinib 1demplatin pegraglumer 1cobimetinib 1birinapant 1Topotecan 1Tablets 1ODM-207 1Infusions, Intravenous 1HLA-A*24:02 antigen 1Gemcitabine 1E-3810 1CB-839 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Tumors × Infusions, Intravenous × Clear all
NCT05524194 2022-09-01

6MW3511 in Patients With Advanced Solid Tumor

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 1/2 Unknown
272 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡